S
Sequent Scientific Ltd
Pharmaceuticals
₹ 175.86 -1.02 (-0.58%)
₹ 175.86 -1.02 (-0.58%)
- NSE
- BSE
Overview
- BSE Code 512529
- NSE Symbol SEQUENT
- ISIN Demat INE807F01027
- Book Value (₹) 45.65
- Face Value (₹) 2.00
- Market Cap (₹ Cr.) 4,695.03
- P/E (TTM) 275.81
- EPS (TTM) 0.68
- Div Yield (%) 0.00
Performance
Today’s Low 175.10
Today’s High 180.26
52W Low 117.35
52W High 240.70
Open 178.70
Prev. Close 176.88
Volume 2,65,289.00
Corporate Actions
Sequent Scientific Limited - Analysts/Institutional Investor Meet/Con. Call Updates
Apr 24, 2025Sequent Scientific Limited has informed the Exchange about Schedule of meet
About Sequent Scientific Ltd
Incorporated in 2002, Sequent Scientific Limited is engaged in the business of providing a wide-ranging portfolio of animal health products, including Finished Dose Formulations and APIs, as well as analytical services to the pharmaceutical and life sciences industries. In 2003, the Hon'ble Bombay High Court approved the Scheme of Amalgamation of the company with P I Drugs and Pharmaceuticals Ltd. The company’s name was changed from PI Drugs and Pharmaceuticals Ltd to Sequent Scientific Ltd.
In 2013, Sequent Scientific Ltd announced a joint venture with Shasun Pharmaceuticals Ltd to establish a leading animal health company. The company continued its operational growth and achieved numerous milestones in 2014. During the year, the company announced the completion of the sale of the speciality chemicals division to Songwon Industrial Group. In addition, it gained complete control of the business of Arvee Synthesis to provide impetus to the Human API business. In 2016, the company gained complete control of a controlling stake in Indo Phyto Chemicals and made a strategic entry into into steroids and hormones. During the same year, it commenced production in the Vizag facility.
The company’s arm, Alivira, received approval from the US health regulator for its animal health API facility in Visakhapatnam in Andhra Pradesh in 2017. In 2020, the company announced the addition of a new state-of-the-art Animal Health R&D Centre in Mumbai. During the same year, it received EIR from the US FDA for its Analytical Laboratory in Bengaluru. In 2021, the company made a strategic entry into into the pet segment in Brazil. During the same year, the European Union Good Manufacturing Practices (EUGMP) received approval for its tablet dosage manufacturing line in Turkey.
Business Segments
- API:Under this segment, the organization is engaged in the manufacturing of API.API enterprise has 29 USVMFs + 18 CEPs (registered 5 VMFs and 3 CEPs in FY23) as of FY 2023. The organization signed a long-term master supply arrangement with a global Top-10 animal health organization. API has 30+ commercial APIs with 3 manufacturing facilities and 1 R&D center. The organization made new investments in capacity expansion for leading customers and in expanding its own R&D capacity. The organization launched 4 new API products in FY 2023.
- Formulation:The organization has over 1000 final dosage formulations, 5 R&D centres devoted to the formulation industry, 6 manufacturing facilities in Europe, Turkey, Brazil, and India, and a marketing presence in more than 100 countries. In an effort to increase profitability, the organization closed its manufacturing operations in its Germany factory in FY23 and relocated to a less expensive location. In FY23, their new Phyto line was introduced.
- Alivira Animal Health Limited:It is a wholly-owned subsidiary which came into existence as on September 30, 2013. It is the largest and 1st Global integrated animal health organization specialising in the manufacturing of Active Pharmaceutical Ingredients (API) and Finished Dosage Formulations (FDF).
- Laboratorios Karizoo S.A:This wholly-owned subsidiary came into existence as on May 09, 1983. Since its inception, the organization has served the veterinary pharmaceutical sector.
Key Personnel
Mr. Rajaram Narayanan, Managing Director Mr Narayanan has over 25 years of experience and possesses a strong track record of leading revenue and profitability growth throughout multiple industries, including pharmaceuticals. Prior to joining the company, he worked with Sanofi India Limited as the Managing Director and Country Chair for India. He led the strategic reorientation of Sanofi’s India business operations. Mr. Narayanan started his career at Hindustan Unilever Ltd., where he held various leadership roles in India and other Asian markets for over 18 years, building and managing many iconic consumer brands. He is a BE (Hons)-Electrical and Electronics graduate from Birla Institute of Technology and Science, Pilani, and an MBA from the Indian Institute of Foreign Trade, New Delhi. He has completed the Advanced Management Program at Harvard Business School, USA.Corporate Actions
The company has no history of bonus issues, stock splits and other corporate actions.| Founded | : 1985 |
| Chairman | : Kamal K Sharma |
| Managing Director | : N Rajaram |
| Address | : 301 Dosti Pinnacle 3rd Floor, Plot E7 Road No 22 Wagle Indl, Thane, Maharashtra, 400604, |
| HO Tel | : |
Open A Free Demat Account Today
Get StartedDocuments To Be Kept Handy
- PAN Card
- Cancelled Cheque
- Latest 6 month Bank Statement (Only for Derivatives Trading)